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Background: Thyroid metastases are clinically rare, and usually occur in patients with a history of prior malignancy
and when there are metastases elsewhere. Metastases of pancreatic carcinoma to the thyroid are extremely rare,
with only three cases reported in the literature.
Case presentation: We report a patient who had a pancreatic carcinoma with metastasis to the thyroid as initial
clinical presentation of the disease. A 63-year-old man with a history of weight loss and fatigue presented with cervical
lymphadenopathies and a large nodule in the right lobe of the thyroid. A fine needle aspiration of the nodule gave
inconclusive cytological results for the origin of the neoplastic cells. An ultrasound-guided core biopsy revealed
the presence of a poorly differentiated adenocarcinoma infiltrating the thyroid with atrophic thyroid follicles.
Immunohistochemical staining of the lesion was strongly positive for Cytokeratin 19 suggesting a pancreatic origin of
the metastasis. A contrast CT scan demonstrated an enlargement of the pancreatic body, dilatation of the pancreatic
duct, diffuse retroperitoneal, paraaortic and cervical lymphadenopathy and secondary lesions in the liver.
Conclusion: Metastases to the thyroid from pancreatic carcinoma are extremely rare. A core biopsy of the lesion
excluded a thyroid carcinoma and permitted the diagnosis of the primary neoplasm.
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The thyroid gland is a known but unusual site for meta-
static tumours from various primary sites. Although
clinically apparent metastases from nonthyroid malig-
nancies (NTMs) to the thyroid gland are uncommon,
metastases to the thyroid have been reported in 1.4-3.0%
of all patients who had surgery for thyroid malignancy
[1,2]. Moreover, a wide range of prevalence, from 1.9%
to 24%, has been reported from autopsy series [3,4]. The
most common NTMs that metastasize to the thyroid are
kidney, colorectal, lung and breast carcinomas.
Metastasis of pancreas carcinoma to the thyroid is ex-
tremely rare and only three cases have been previously
reported. We present a case of thyroid metastasis from a
pancreatic carcinoma in which the metastasis was the
initial clinical presentation.* Correspondence: aledelitala@tiscali.it
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stated.Case presentation
We present the case of a Caucasian 63-year-old man
who had an 8 –week history of 10 kilogram weight loss,
profound fatigue and cervical lymphadenopathy.
As an outpatient he underwent a neck ultrasonography
(US) in another center which identified a big hypoechoic
lesion in the right lobe with ill-defined margins. Cyto-
logical analysis of the lesion was defined as malignancy
(Figure 1A) according to the Bethesda System for report-
ing thyroid cytopathology [5] and the patient was referred
for possible thyroidectomy. Thyroid function tests showed
the following results: thyrotropin level 5.5 μU/ml (normal
0.46-4.68), free triiodothyronine 3.12 pg/ml (normal 2.75-
5.26), and free thyroxine 1.07 ng/dl, (normal 0.77-2.19).
Antibodies against thyroperoxidase and against thyro-
globulin were negative, and serum calcitonin was normal
(8 pg/ml, normal < 18).
Subsequently, he referred to our ward to perform fur-
ther analysis. Neck US was repeated using a high fre-
quency linear probe (15 L8W, 7.5-14 MHz, Acuson
Sequoia 512, Siemens, Mountain View, California, USA).Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 Cytological and histological aspects of the nodule. (A) Thyroid fine needle aspiration (Papanicolaou, magnitude 600 X). A high
power field showing a cluster of neoplastic cells in a necrotic background. (B) Thyroid core biopsy (hematoxilin and eosin, magnitude 400 X):
thyroid tissue infiltrated by poorly differentiated adenocarcinoma (arrows). (C) Thyroid core biopsy (CK19, magnitude 200 X): Strong cytoplasmic
positivity in neoplastic cells. (D) Thyroid core biopsy (TTF-1, magnitude 200 X): nuclear positivity in follicular cells.
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longitudinal size was detected in the right lobe of the
gland, associated with round and enlarged lymph nodes
in laterocervical part of the neck, especially on the right
side. After conventional US, a contrast enhancement US
(CPS, Siemens, Mountain View, California; Sonovue,
Bracco, Italy) focused to the thyroid gland and lymph
node was performed (Figure 2). Nodule and lymph node
showed a similar pattern. In the central part, they exhib-
ited a hypovascular aspect in all phases of contrast US
(typical for malignant lesions), except for the presence
of small vessels. The enhancement was located only in
the peripheral part of both nodule and lymph node.
An US-guided core biopsy (Selectcore Inrad, 20 gauge,
10 cm in length) of the nodule was performed.
On microscopic examination, histological sections re-
vealed a pseudoglandular proliferation of atypical epi-
thelial cells embedded in a fibrous stroma with atrophic
thyroid follicles (Figure 1B). Furthermore, on immuno-
histochemical findings, thyrocytes showed immunoreac-
tivity for thyroid transcription factor-1 (TTF-1) in spite
of negativity in the neoplastic cells (Figure 1D). All
these features were consistent with the diagnosis of
metastatic pancreatic adenocarcinoma. Therefore, we
measured tumor markers which revealed elevated carci-
noembryonic antigen (15.98 ng/mL, normal <5), cancer
antigen 19–9 (8731.52 U/ml, normal <37), and slightlyelevated cancer antigen 125 (240.10 U/ml, normal <35).
Additional laboratory blood tests were consistent with
biliary obstruction and liver damage.
A contrast CT scan demonstrated an enlargement of the
pancreatic body with a 22 mm hypodense lesion with ill-
defined margins, dilatation of the pancreatic duct, diffuse
retroperitoneal, paraaortic and cervical lymphadenopathy
and secondary lesions in the liver (1–4.2 cm) (Figure 3). A
needle biopsy of the largest hepatic lesion revealed hepatic
tissue infiltrated by poorly differentiated adenocarcinoma
which was similar to the neoplastic tissue found in the
right lobe of the thyroid.
The patient referred to the oncology unit for palliative
treatment, and died two months later.
Discussion
The thyroid gland is believed to be a rare site of metastatic
disease. It has been hypothesized that the fast arterial flow
through the thyroid and the high oxygen saturation and
iodine content within the thyroid might inhibit the growth
of metastatic malignant cells [3]. NTMs seem to occur
more frequently in glands that were also abnormal. These
abnormalities included goiter, thyroiditis, benign and ma-
lignant primary neoplasm. In particular, malignant metas-
tases were most commonly found concomitantly with
goiters and follicular thyroid adenomas [6]. These data
support the hypothesis that the abnormal blood supply
Figure 2 Thyroid ultrasound with contrast enhancement and biopsy. Longitudinal view of the right lobe of the thyroid gland performed
with linear probe (7.5-14 Mhz) in conventional ultrasound (panel A, D) and after contrast enhancement ultrasound (panel B,C). Panel A shows a
hypoechoic lesion of the right lobe of the thyroid gland. The yellow arrow indicates a metastatic lymph node located close to the upper pole of
the right lobe. Panel B shows the hypovascular aspect of the nodule and lymph node after contrast injection. The enhancement is located only
in the peripheral part both of nodule and lymph node as well. Panel C shows the enhancement in the venous phase which is still located only in
the peripheral part of the nodule, except for the presence of small tiny vessels located also in the central part. Panel D show the path of the
needle inserted inside of the nodule.
Figure 3 CT scan of the body. In panel A and B the yellow arrows indicate the big mass of the right lobe of the thyroid gland. In panel C the
yellow arrow indicates one of the multiple secondary liver lesions. In panel D the yellow arrow indicates the pancreatic cancer located in the
body with dilatation of the pancreatic duct.
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in decreased oxygen and iodine content.
The reported prevalence of metastasis to the thyroid is
variable, since the prevalence of thyroid metastasis from
NTMs ranges from 1.9% to 24% in autopsy studies in pa-
tients with a known history of neoplasm. This wide range
may be mainly explained by different population studied
(few cases in most of the studies) and by the predomin-
ance of the type of primary cancer included in the series
(patients with renal cancer had an increased prevalence of
metastasis to thyroid gland).
However, a very recent review of the literature clearly
suggests that clinically significant metastases of NTMs
to the thyroid are not rare. In particular, the most com-
mon NTMs that metastasize to the gland are renal cell,
colorectal, lung, breast carcinoma and sarcoma [2,6].
Thus, metastasis to the thyroid should be considered
when a thyroid lesion is detected in the follow-up of pa-
tients with a history of cancer.
According a MEDLINE search, there are only three
reported cases of thyroid metastasis from pancreatic ma-
lignant tumour.
The first was reported by Eriksson et al. [7] in a 54
year-old men with disseminated pancreatic carcinoma.
Interestingly, this patient had a transient thyrotoxicosis
due to a destructive thyroiditis caused by the massive
invasion of the organ by tumour cells. Percutaneous bi-
opsy of the gland excluded the presence of thyroiditis
and demonstrated the presence of carcinoma. Autopsy
showed an adenocarcinoma of the pancreatic tail with
widespread metastasis. In particular, in the areas in-
volved by the tumour, invasion and disruption of thyroid
follicles by tumour cells were frequent.
The second patient was reported by Hsiao et al. [8] in
a 45-year-old male with a previously diagnosed intraductal
papillary-mucinous carcinoma of the pancreas. Adenocar-
cinoma metastatic to the thyroid was proven pathologic-
ally only after thyroidectomy, as cytodiagnosis of the
thyroid aspirate did not proven the primary site of the le-
sion. The patient died one week after the surgery.
The third case has been reported by Kelly et al. [9] in a
38-year-old man with obstructive jaundice and epigastric
pain who underwent a pancreatic-duodenectomy and,
eight weeks later, a total thyroidectomy. The histology of
the thyroid was similar to that of the pancreatic specimen.
Metastatic lesions in the thyroid gland could range from
overt hypothyroidism with myxedema (3) to hyperthyroid-
ism/thyrotoxicosis (7), although most of patients did not
show any thyroid dysfunction. The prognosis essentially
refers to the primary site of the cancer, and the overall sur-
vival time is not significantly different in cancer patients
with or without thyroid metastasis [10].
Fine needle aspiration (FNA) is the most common and
useful investigation in the diagnosis of thyroid pathology.The technique is also useful in the diagnosis of malig-
nant metastasis to the thyroid. However, FNA may not
yield a definitive diagnosis in all cases, particularly when
the metastatic cells are poorly differentiated. Therefore
histology and immunochemistry is usually necessary in
order to differentiate primary thyroid carcinomas from
metastatic neoplasm. Percutaneous core biopsy has been
shown to be superior to the FNA in patients with prior
non diagnostic FNA of thyroid nodules [11]. In our pa-
tient microscopic examination of the specimen obtained
by core biopsy revealed the presence of a poorly differ-
entiated carcinoma with a strong cytoplasmatic positivity
for Cytokeratin 19 [12], and negative staining for thyro-
globulin and TTF-1 [13], thus favouring the diagnosis of
metastatic tumour over a primary thyroid cancer. The
association of this immunohistochemical finding and
clinical and biochemical data clearly indicated that the
thyroid lesion was a metastatic pancreatic carcinoma.
Conclusions
Our case represents the fourth case reported in the lit-
erature of pancreatic adenocarcinoma metastatic to the
thyroid, and the first in whom the thyroid metastasis
was the initial clinical presentation of the pancreatic
disease. The core biopsy of the thyroid lesion, providing
more tissue (with retained cellular architecture) compared
to the FNA, allowed the identification of the primary neo-
plasm. Moreover, we describe for the first time the behav-
ior of the ultrasound contrast agent in a thyroid lesion,
secondary to a metastatic pancreatic adenocarcinoma.
Metastases of NTM to thyroid gland are uncommon
and their identification could be challenging. We suggest
that the use of ultrasound-guided core biopsy could help
the physician in the diagnosis.
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